Pipeline
SeveriDx stands out due to its unique technology, strong intellectual property portfolio, and strategic partnerships with leading academic and hospital institutions, clinical study providers, and industry.
2024 Q3
SeveriDx foundation
a spin-off of GeneSpector
2024 H2
Setup team and advisory board
partnering (CRO, IVDR certification partner, legal manufacture, marketing, etc.)
2024 H2
Clinical trial preparation for CE IVDR and FDA
2024 Q4
Investment round
2025 – 2026
Clinical studies and certification process
2027 – 2028